Only one study has to date [126], however, has examined the association between AD biomarkers and Tau PET using novel tau tracers now entering the field [127]; this study showed that while Tau PET using [18F]RO948 outperformed CSF AD biomarkers (Aβ42/Aβ40 and Aβ42/P-tau) for separating AD dementia from non-AD disorders, the reverse was seen when differentiating Aβ-positive MCI from non-AD disorders [126]. The gene discussed is MAPT; the disease is Alzheimer disease.